|
|
Article: Eli Lilly and Company: Pioneering New Advances in Breast Cancer: Combination Therapy Maximizes Treatment Outcomes for Metastatic Breast Cancer Patients.
- Article from:
- Business Wire
- Article date:
- September 23, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
COPENHAGEN, Denmark--(BUSINESS WIRE)--Sept. 23, 2003
International Experts Convene to Reinforce Critical
Role of Gemzar-Based Combination Therapy at ECCO 12
Data presented today at the Braving New Worlds: Pioneering New Advances in Breast Cancer media briefing highlight the importance of combination therapy in the fight against breast cancer.
Interim results from a Phase III trial with Gemzar(R) (gemcitabine HCl) plus Taxol(R) (paclitaxel) have shown significant efficacy advantages over Taxol alone, with a 50 percent improvement in median time to disease progression and with more than 44 ...